More News:

July 28, 2022

Clinical study for early Alzheimer’s disease seeking volunteers

Phase 1 study will evaluate medication designed to have disease-modifying benefits

Alzheimer's Study

Content sponsored by Limited - Acumen - Intercept Ad Study Sponsorship Logo

Purchased - A doctor confronts a smiling senior monkeybusinessimages/

Memory loss is more common than any of us would like to admit — and watching someone you love experience memory problems can make you feel helpless. But by participating in a clinical study, you or your loved one can help to reshape Alzheimer’s treatment, helping scientists better understand how it affects the brain.

INTERCEPT-AD is a phase 1 study that is seeking volunteers who have memory problems to assist in evaluating the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193, an investigational medication for the treatment of Alzheimer’s disease. There is no cost to participate.

ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain in people with Alzheimer’s disease. These proteins are thought to be involved in Alzheimer’s disease symptoms and progression.

To be eligible for the study, participants must:

• Be between 55 to 90 years of age.

• Have memory problems that might be a sign of mild cognitive impairment (usually mild memory loss) or mild dementia. The underlying cause of these memory problems may or may not be due to Alzheimer’s disease. Tests given within the study will help to determine this.

• Have a family member or study partner; someone who knows the participant well, who is willing to assist with participation in the study and can attend the study visits with the participant.

Limited - Acumen - Dr. David Weisman

Dr. David Weisman

The trial site, Abington Neurological Associates, located at 1151 Old York Road, Suite 200, Abington, PA 19001, is led by principal investigator Dr. David Weisman. The staff at the study center will explain the complete list of requirements. Study participants will receive a full diagnostic work-up, including an amyloid PET scan and MRI that can provide a more accurate diagnosis and help guide future treatment options.

Click here to see if you qualify for the INTERCEPT-AD phase 1 study for early Alzheimer’s disease. For additional information, call (215) 957-9250 Ext 151 or email